These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20544311)

  • 1. Left atrial appendage closure.
    Singh IM; Holmes DR
    Curr Cardiol Rep; 2010 Sep; 12(5):413-21. PubMed ID: 20544311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Left Atrial Appendage: Target for Stroke Reduction in Atrial Fibrillation.
    Ramlawi B; Abu Saleh WK; Edgerton J
    Methodist Debakey Cardiovasc J; 2015; 11(2):100-3. PubMed ID: 26306127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy.
    Viles-Gonzalez JF; Kar S; Douglas P; Dukkipati S; Feldman T; Horton R; Holmes D; Reddy VY
    J Am Coll Cardiol; 2012 Mar; 59(10):923-9. PubMed ID: 22381428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.
    Søndergaard L; Wong YH; Reddy VY; Boersma LVA; Bergmann MW; Doshi S; Kar S; Sievert H; Wehrenberg S; Stein K; Holmes DR
    JACC Cardiovasc Interv; 2019 Jun; 12(11):1055-1063. PubMed ID: 31171282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience.
    Price MJ; Reddy VY; Valderrábano M; Halperin JL; Gibson DN; Gordon N; Huber KC; Holmes DR
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1925-1932. PubMed ID: 26627989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk.
    Seeger J; Bothner C; Dahme T; Gonska B; Scharnbeck D; Markovic S; Rottbauer W; Wöhrle J
    Clin Res Cardiol; 2016 Mar; 105(3):225-9. PubMed ID: 26318322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left atrial appendage closure devices. Their role in 2013.
    Mangner N; Sandri M; Lurz P; Dähnert I; Schuler G; Möbius-Winkler S
    Minerva Cardioangiol; 2013 Apr; 61(2):125-34. PubMed ID: 23492596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catheter ablation in combination with left atrial appendage closure for atrial fibrillation.
    Swaans MJ; Alipour A; Rensing BJ; Post MC; Boersma LV
    J Vis Exp; 2013 Feb; (72):e3818. PubMed ID: 23486416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left Atrial Appendage Exclusion for Atrial Fibrillation.
    Syed FF; DeSimone CV; Friedman PA; Asirvatham SJ
    Heart Fail Clin; 2016 Apr; 12(2):273-97. PubMed ID: 26968671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Transcatheter Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation.
    Price MJ
    Prog Cardiovasc Dis; 2018; 60(4-5):542-549. PubMed ID: 29339165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left atrial appendage exclusion: state-of-the-art.
    Cruz-Gonzalez I; Yan BP; Lam YY
    Catheter Cardiovasc Interv; 2010 Apr; 75(5):806-13. PubMed ID: 20088009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel approach to left atrial appendage exclusion: the WATCHMAN device.
    Gorodnitskiy A; Lucariello RJ; Aizer A; Coppola JT
    Cardiol Rev; 2010; 18(5):230-3. PubMed ID: 20699670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left atrial appendage-occluding devices for stroke prevention in patients with nonvalvular atrial fibrillation.
    Yan BP; Kiernan TJ; Gonzales-Cruz I; Lam YY
    Expert Rev Med Devices; 2009 Nov; 6(6):611-20. PubMed ID: 19911873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a Novel Septal Occluder Device for Left Atrial Appendage Closure in Patients With Postsurgical and Postlariat Leaks or Anatomies Unsuitable for Conventional Percutaneous Occlusion.
    Della Rocca DG; Horton RP; Tarantino N; Van Niekerk CJ; Trivedi C; Chen Q; Mohanty S; Anannab A; Murtaza G; Akella K; Gianni C; Bassiouny M; Ahmadian-Tehrani A; Al-Ahmad A; Burkhardt JD; Natale VN; Price M; Gallinghouse GJ; Gibson DN; Lakkireddy D; Di Biase L; Natale A
    Circ Cardiovasc Interv; 2020 Oct; 13(10):e009227. PubMed ID: 32942913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The WATCHMAN left atrial appendage closure device for atrial fibrillation.
    Möbius-Winkler S; Sandri M; Mangner N; Lurz P; Dähnert I; Schuler G
    J Vis Exp; 2012 Feb; (60):. PubMed ID: 22395336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation.
    Alli O; Doshi S; Kar S; Reddy V; Sievert H; Mullin C; Swarup V; Whisenant B; Holmes D
    J Am Coll Cardiol; 2013 Apr; 61(17):1790-8. PubMed ID: 23500276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left atrial appendage occlusion with the WATCHMAN™ for stroke prevention in atrial fibrillation.
    Price MJ
    Rev Cardiovasc Med; 2014; 15(2):142-51. PubMed ID: 25051131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study.
    Block PC; Burstein S; Casale PN; Kramer PH; Teirstein P; Williams DO; Reisman M
    JACC Cardiovasc Interv; 2009 Jul; 2(7):594-600. PubMed ID: 19628179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left atrial appendage closure for "primary primary" prevention during percutaneous closure of septal defects in patients with large atria but no atrial fibrillation.
    Kuwata S; Vierecke J; Gloekler S; Maisano F; Meier B; Nietlispach F
    Cardiol J; 2018; 25(2):179-187. PubMed ID: 28840592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left atrial appendage exclusion for atrial fibrillation.
    Syed FF; DeSimone CV; Friedman PA; Asirvatham SJ
    Cardiol Clin; 2014 Nov; 32(4):601-25. PubMed ID: 25443240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.